Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis

CNS Drugs

Volumn 33, Issue 6, 2019, Pages 549-566

  Demyttenaere, Koen ^a   Detraux, Johan ^b   Racagni, Giorgio ^c   Vansteelandt, Kristof ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; BREXPIPRAZOLE; CARIPRAZINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

AKATHISIA; BIPOLAR DISORDER; DISEASE SEVERITY; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; SEVERITY OF ILLNESS INDEX;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; HUMANS; LURASIDONE HYDROCHLORIDE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 85065499411     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-019-00625-3     Document Type: Review

References (172)

1. Pringsheim T, Gardner D, Addington D, Martino D, Morgante F, Ricciardi L, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018. 10.1177/0706743718760288 (Epub 2018 Jan 1).
2. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15(5):789–98.
3. Forcen FE, Matsoukas K, Alici Y. Antipsychotic-induced akathisia in delirium: a systematic review. Palliat Support Care. 2016;14(1):77–84.
4. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of akathisia. CNS Spectr. 2015;20(Suppl 1):1–14.
5. Barnes TR. The Barnes Akathisia Rating Scale–revisited. J Psychopharmacol. 2003;17(4):365–70.
6. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.
7. Tachere RO, Modirrousta M. Beyond anxiety and agitation: a clinical approach to akathisia. Aust Fam Phys. 2017;46(5):296–8.
8. Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin N Am. 2016;39(3):391–411.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
10. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127–48 (viii).
11. Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019–29.
12. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin N Am. 2005;28(1):255–74 (x).
13. Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology. 2017;234(17):2563–70.
14. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005;76(2–3):247–65.
15. Weiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs. 2016;30(8):735–47.
16. Gbinigie II, Lasserson D. Clarithromycin-induced akathisia: a class effect of macrolides. BMJ Case Rep. 2016. 10.1136/bcr-2016-217421.
17. Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol. 2015;6:75.
18. Riesselman A, El-Mallakh RS. Akathisia with azithromycin. Ann Pharmacother. 2015;49(5):609.
19. Dressler D. Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine. J Neural Transm (Vienna). 2014;121(4):367–9.
20. Wright MT. Antiemetics, akathisia, and pregnancy. Psychosomatics. 2007;48(6):461–6.
21. Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2012;26(5 Suppl):15–26.
22. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77.
23. Berna F, Misdrahi D, Boyer L, Aouizerate B, Brunel L, Capdevielle D, FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015;169(1–3):255–61.
24. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–18.
25. Nasrallah HA, Earley W, Cutler AJ, Wang Y, Lu K, Laszlovszky I, et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;17(1):305.
26. Martino D, Karnik V, Osland S, Barnes TRE, Pringsheim TM. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 2018;1:706743718777392.
27. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull. 2003;29(3):547–58.
28. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70(5):627–43.
29. Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks: Sage Publications; 2001.
30. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–67.
31. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47(5):670–7.
32. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology. 2013;225(3):519–30.
33. Potkin SG, Kimura T, Guarino J. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther Adv Psychopharmacol. 2015;5(6):322–31.
34. Landbloom RL, Mackle M, Wu X, et al. Asenapine: efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord. 2016;190:103–10.
35. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29–35.
36. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20–8.
37. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12–9.
38. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S4–11.
39. Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Hum Psychopharmacol. 2012;27(1):24–32.
40. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3–10.
41. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–86.
42. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815–26.
43. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010;126(3):358–65.
44. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38.
45. Szegedi A, Calabrese JR, Stet L, Mackle M, Zhao J, Panagides J, Apollo Study Group. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol. 2012;32(1):46–55.
46. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. J Affect Disord. 2013;145(1):62–9.
47. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15.
48. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349–55.
49. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138–46.
50. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196–203.
51. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45.
52. Berk M, Tiller JW, Zhao J, Yatham LN, Malhi GS, Weiller E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis. J Clin Psychiatry. 2015;76(6):728–34.
53. Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016;233(14):2663–74.
54. Landbloom R, Mackle M, Wu X, Kelly L, Snow-Adami L, McIntyre RS, et al. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. CNS Spectr. 2017;22(4):333–41.
55. Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA. Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat. 2017;13:2021–35.
56. Szegedi A, Durgam S, Mackle M, Yu SY, Wu X, Mathews M, Landbloom RP. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar i disorder. Am J Psychiatry. 2018;175(1):71–9.
57. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–13.
58. Durgam S, Earley W, Guo H, Li D, Németh G, Laszlovszky I, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371–8.
59. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015;17(1):63–75.
60. Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–82.
61. Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152(2–3):450–7.
62. Calabrese JR, Keck PE Jr, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–92.
63. Kane JM, Zukin S, Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35(4):367–73.
64. Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296–302.
65. Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271–81.
66. Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017;32(6):319–28.
67. Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: a pooled post hoc analysis of 3 phase II/III studies. J Affect Disord. 2017;215:205–12.
68. Lao KS, He Y, Wong IC, Besag FM, Chan EW. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(11):1043–54.
69. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016;176(2–3):264–71.
70. Durgam S, Litman RE, Papadakis K, Li D, Németh G, Laszlovszky I. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Int Clin Psychopharmacol. 2016;31(2):61–8.
71. Forest Laboratories. Safety and efficacy of RGH-188 (cariprazine) in bipolar depression. 2010 [ClinicalTrials.gov identifier NCT00852202]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
72. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692–700.
73. Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, et al. A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry. 2018;79(4):17m12058. 10.4088/JCP.17m12058.
74. Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34(4):633–42.
75. Fleischhacker WW, Hobart M, Ouyang J, Forbes A, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole (opc-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017;20(1):11–21.
76. Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016;174(1–3):93–8.
77. Correll CU, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1–3):82–92.
78. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol. 2016;31(4):192–201.
79. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–40.
80. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–31.
81. McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116–23.
82. Marder SR, Hakala MJ, Josiassen MK, Zhang P, Ouyang J, Weiller E, et al. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatr. 2017;29(5):278–90.
83. Nelson JC, Weiller E, Zhang P, Weiss C, Hobart M. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: a post hoc analysis of two pooled clinical studies. J Affect Disord. 2018;227:103–8.
84. Nelson JC, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, et al. Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev. 2016;12:278–90.
85. Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, et al. Adjunctive brexpiprazole as a novel effective strategy for treating major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(1):46–53.
86. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1–3):127–35.
87. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–80.
88. H. Lundbeck A/S. Lighthouse trial. Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia. 2014 [ClinicalTrials.gov identifier NCT01810380]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
89. Otsuka Pharmaceutical Development & Commercialization, Inc., Study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of patients with major depressive disorder [ClinicalTrials.gov identifier NCT00797966]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
90. Otsuka Pharmaceutical Development & Commercialization, Inc., Study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of adults with major depressive disorder (STEP-D222) [ClinicalTrials.gov identifier NCT01052077]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
91. Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:86–93.
92. Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–7.
93. Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016;77(12):1672–80.
94. Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015;15:271.
95. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–8.
96. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–77.
97. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–9.
98. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95–102.
99. Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–76.
100. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2–3):101–7.
101. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829–36.
102. Sunovion, A randomized, double-blind, placebo-controlled, flexible-dose, parallel-group study of lurasidone adjunctive to lithium or divalproex for the prevention of recurrence in subjects with bipolar i disorder. 2015 [ClinicalTrials.gov identifier NCT01358357]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
103. Sunovion, A 6-week, double-blind, randomized, fixed-dose, parallel-group study of the efficacy and safety of three dose levels of sm-13496 compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. 2003 [ClinicalTrials.gov identifier NCT00044044]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 26 Sep 2018
104. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138–47.
105. Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol. 2015;13(5):681–91.
106. Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag. 2017;13:299–306.
107. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull. 2012;38(1):167–77.
108. Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry. 2018;26(1):92–4.
109. Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23(1):39–50.
110. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114–26.
111. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206.
112. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.
113. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA. Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013;69(8):1497–509.
114. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology. 2017;234(2):199–209.
115. Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci. 2016;13(9–10):49–52.
116. ® (cariprazine) capsules, for oral use. Highlights of prescribing information. Revised 11/2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204370s002s003lbl.pdf. Accessed 28 Sep 2018.
117. Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–28.
118. Findlay LJ, El-Mallakh PL, El-Mallakh RS. Cariprazine for the treatment of bipolar disorder. Perspect Psychiatr Care. 2017;53(3):148–55.
119. Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study. J Affect Disord. 2018;225:350–6.
120. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203–9.
121. ® (Lurasidone HCl tablets). Highlights of prescribing information. Revised 3/2018. https://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed 28 Sep 2018
122. Jaeschke RR, Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Styczeń K, Datka W. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacol Rep. 2016;68(4):748–55.
123. Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015;20(2):140–7.
124. Zheng W, Cai DB, Yang XH, Li L, Zhang QE, Ng CH, et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: a meta-analysis of randomized controlled trials. J Psychiatr Res. 2018;103:244–51.
125. Correll CU, Cucchiaro J, Silva R, Hsu J, Pikalov A, Loebel A. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectr. 2016;21(5):393–402.
126. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74(5):507–15.
127. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170–9.
128. Fornaro M, De Berardis D, Perna G, Solmi M, Veronese N, Orsolini L, et al. Lurasidone in the treatment of bipolar depression: systematic review of systematic reviews. Biomed Res Int. 2017;2017:3084859.
129. Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Ther Clin Risk Manag. 2015;11:75–81.
130. Sanford M, Dhillon S. Lurasidone: a review of its use in adult patients with bipolar I depression. CNS Drugs. 2015;29(3):253–63.
131. Bawa R, Scarff JR. Lurasidone: a new treatment option for bipolar depression-a review. Innov Clin Neurosci. 2015;12(1–2):21–3.
132. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.
133. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18(Suppl 1):4–20.
134. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–9.
135. Ketter TA, Miller S, Dell’Osso B, Calabrese JR, Frye MA, Citrome L. Balancing benefits and harms of treatments for acute bipolar depression. J Affect Disord. 2014;169(Suppl 1):S24–33.
136. McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015;76(4):398–405.
137. Weiden PJ, Citrome L, Alva G, Brams M, Glick ID, Jackson R, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153(1–3):160–8.
138. Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evid. 2016;11:49–61.
139. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43–54.
140. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review. Clin Schizophr Relat Psychoses. 2012;6(1):34–44.
141. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72(Suppl 1):19–23.
142. ® (Iloperidone). Highlights of prescribing information. Revised 2/2017. https://www.fanapt.com/product/pi/pdf/fanapt.pdf. Accessed 28 Sep 2018.
143. McIntyre RS. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2011;17(6):645–8.
144. Plosker GL, Deeks ED. Asenapine: a review in schizophrenia. CNS Drugs. 2016;30(7):655–66.
145. Scheidemantel T, Korobkova I, Rej S, Sajatovic M. Asenapine for bipolar disorder. Neuropsychiatr Dis Treat. 2015;11:3007–17.
146. McIntyre R, Landbloom R, Mackle M, Wu X, Kelly L, Snow-Adami L, et al. Efficacy and safety of asenapine 5 mg bid and 10 mg bid in adults with a manic or mixed episode associated with bipolar I disorder. Bipolar Disord. 2015;17(Suppl 1):92.
147. SAPHRIS (asenapine) sublingual tablets. Highlights of prescribing information. Revised 02/2017. https://www.allergan.com/assets/pdf/saphris_pi. Accessed 28 Sep 2018.
148. Pompili M, Venturini P, Innamorati M, Serafini G, Telesforo L, Lester D, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259–65.
149. Cazorla P, Mackle M, Zhao J, Ha X, Szegedi A. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2012;8:247–57.
150. ® (Brexpiprazole tablets). Highlights of prescribing information. Revised 2/2018. https://www.otsuka-us.com/media/static/Rexulti-PI.pdf. Accessed 28 Sep 2018.
151. Scarff JR. Brexpiprazole: a new treatment option for schizophrenia. Innov Clin Neurosci. 2016;13(7–8):26–9.
152. Correll CU, Skuban A, Ouyang J, Weiss C, Weiller E, Kane JM. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. Eur Neuropsychopharmacol. 2015;25(Suppl 2):S522–3.
153. Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433–41.
154. Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445–53.
155. Das S, Barnwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54.
156. Markovic M, Gallipani A, Patel KH, Maroney M. Brexpiprazole. Ann Pharmacother. 2017;51(4):315–22.
157. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122(4):39–48.
158. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008;28(1):13–20.
159. Takeuchi H, Thiyanavadivel S, Agid O, Remington G. Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2018;193:29–36.
160. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–47.
161. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. Drug Saf. 2008;31(7):597–607.
162. Zawar I, Caro MA, Feldman L, Jimenez XF. Acute movement disorders in the medical setting. Int J Psychiatry Med. 2016;51(5):395–413.
163. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat. 2001;22(1–2):127–37.
164. Patel J, Galdikas FJ, Marwaha R. Akathisia. [Updated 2019 Apr 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK519543/.
165. Stahl SM. Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013;18(6):285–8.
166. Stahl SM, Lonnen AJ. The mechanism of drug-induced akathisia. CNS Spectr. 2011;16(1):7–10.
167. Corripio I, Ferreira A, Portella MJ, Pérez V, Escartí MJ, Del Valle Camacho M, et al. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res. 2012;201(1):73–7.
168. 2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675–81.
169. Choi YK, Tarazi FI. Long-term effects of iloperidone on cerebral serotonin and adrenoceptor subtypes. J Mol Neurosci. 2018;66(1):59–67.
170. Kee Choi Y, Tarazi FI. Long-term effects of iloperidone on cerebral dopamine receptor subtypes. Synapse. 2018. 10.1002/syn.22039 (Epub 2018 Jun 23).
171. Saklad SR. Graphic representation of pharmacology: development of an alternative model. Ment Health Clin. 2018;7(5):201–6.
172. Richelson E. New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry. 2010;71(9):1243–4.